Two lawsuits have been filed in the US alleging CSL and a competitor conspired to restrict output and artificially increase the price of plasma-derived therapies. CSL says the Federal Trade Commission (FTC) carried out an in-depth analysis of the US plasma industry, which was required to determine the merits of the potential Talecris merger. The FTC found no reason to take any subsequent action against industry participants or make any allegations of collusion. CSL says litigation is part and parcel of US business and it believes the case will drag through the courts over many years and will be robustly defended by both parties.
well done! profit up 63%, page-89
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$308.02 |
Change
0.160(0.05%) |
Mkt cap ! $148.8B | |||
| Open | High | Low | Value | Volume |
| $307.95 | $310.00 | $306.26 | $190.3M | 617.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1111 | $307.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $308.30 | 350 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |